Trade Names:Ceftin- Tablets 125 mg- Tablets 250 mg- Tablets 500 mg- Suspension 125 mg/5 mL- Suspension 250 mg/5 mL
Trade Names:Zinacef- Powder for Injection 750 mg (2.4 mEq sodium/g)- Powder for Injection 1.5 g (2.4 mEq sodium/g)- Powder for Injection 7.5 g (2.4 mEq sodium/g)- Injection 750 mg (2.4 mEq sodium/g)- Injection 1.5 g (2.4 mEq sodium/g)Apo-Cefuroxime (Canada)ratio-Cefuroxime (Canada)
Inhibits mucopeptide synthesis in bacterial cell wall.
C max is 2.1 mcg/mL (125 mg dose) to 13.6 mcg/mL (1,000 mg dose). T max is 2.2 to 3 h. AUC is 6.7 mcg•h/mL (125 mg dose) to 50 mcg•h/mL (1,000 mg dose).Suspension (10 to 20 mg/kg)
C max is 3.3 to 7 mcg/mL. T max is 2.7 to 3.6 h. AUC is 12.4 to 32.8 mcg•h/mL.IM (750 mg dose)
C max is 27 mcg/mL. T max is about 45 min.IV
C max is about 50 mcg/mL (750 mg dose) and about 100 mcg/mL (1.5 g dose). T max is 15 min.
Cefuroxime is detectable in therapeutic concentrations in pleural and joint fluid, bile, sputum, bone, aqueous humor, and CSF (in those with meningitis). It is 50% protein bound.
The t ½ is 1.2 to 1.3 h (tablets), 1.4 to 1.9 h (suspension), and about 80 min (IV/IM). About 50% is excreted unchanged in the urine within 12 h (tablets/suspension) and about 89% over 8 h (IV/IM).
The t ½ is prolonged. Dosage reduction is recommended.
Treatment of infections of lower respiratory tract, urinary tract, skin and skin structures; treatment of uncomplicated gonorrhea, otitis media, pharyngitis, and tonsillitis caused by susceptible strains of specific microorganisms. Treatment of early Lyme disease, pharyngitis/tonsillitis, and impetigo.Parenteral form
Treatment of infections of lower respiratory tract, urinary tract, skin and skin structures, bone and joint; preoperative prophylaxis; treatment of septicemia, gonorrhea, and meningitis caused by susceptible strains of specific microorganisms.
Hypersensitivity to cephalosporins.
PO 125 to 500 mg twice daily. IV / IM 750 mg to 1.5 g every 8 h.Children younger than 12 yr of age
PO 125 to 250 mg twice daily.Infants and Children older than 3 mo of age
IV / IM 50 to 150 mg/kg/day (not to exceed adult dose) in equally divided doses every 6 to 8 h.Bacterial MeningitisAdults and Children 12 yr of age and older
IV / IM Up to 3 g every 8 h.Infants and Children 3 mo to 12 yr of age
IV / IM 200 to 240 mg/kg/day in divided doses every 6 to 8 h.Uncomplicated GonorrheaAdults and Children 12 yr of age and older
PO 1 g as single dose. IM 1.5 g as single dose.Preoperative ProphylaxisAdults
IV / IM 1.5 g 30 min to 1 h before surgery then 750 mg every 8 h for duration of surgery.
Increased risk of nephrotoxicity with parenteral cefuroxime.Probenecid
Inhibition of renal excretion of cefuroxime.
Do not add aminoglycosides to cefuroxime solutions because inactivation of both drugs may result; administer at separate sites if concurrent therapy is indicated.
May cause false-positive urine glucose test results with Benedict solution, Fehling solution, or Clinitest tablets but not with enzyme-based tests (eg, Clinistix , Tes-tape ); false-positive test results for proteinuria with acid and denaturization-precipitation tests; false-positive direct Coombs test results in certain patients (eg, those with azotemia); false elevations in urinary 17-ketosteroid values; false-negative reaction in ferricyanide test for blood glucose.
Nausea; vomiting; diarrhea; anorexia; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis.
Pyuria; renal dysfunction; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy.
Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; decreased platelet function; anemia; aplastic anemia; hemorrhage.
Hepatic dysfunction; abnormal LFT results.
Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis; candidal overgrowth; serum sickness–like reactions (eg, skin rashes, polyarthritis, arthralgia, fever); phlebitis, thrombophlebitis, and pain at injection site.
MonitorResponse to therapy
Monitor patient's response to therapy. Notify health care provider if infection does not appear to improve or worsens.Adverse reactions
Monitor patient for GI, DERM, and general body adverse reactions, and signs of superinfection. Inform health care provider if noted and significant. Immediately report severe diarrhea, diarrhea containing blood or pus, or severe abdominal cramping.
Category B .
Excreted in breast milk.
Safety and efficacy in children younger than 3 mo of age not established.
Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients because of possible cross-reactivity.
Use drug with caution in patients with renal function impairment. Dosage adjustment based on renal function may be required.
May result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Consider in patients in whom diarrhea develops.
Copyright © 2009 Wolters Kluwer Health.